BPC-157 vs CJC-1295

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

BPC-157

Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.

Full details →

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Side-by-Side Comparison

Aspect	BPC-157	CJC-1295
Dose Range	250 mcg–500 mcg	1 mg–2 mg
Frequency	2x daily	Less than daily
Cycle Length	4–6 weeks	8–12 weeks
Route	subcutaneous	subcutaneous
Mechanism	BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels.	CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.
Typical Dosage	Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied.	CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.
Administration	Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable.	Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.
Side Effects	Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses.	Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.
Best For	Muscle Growth Recovery & Healing	Muscle Growth Fat Loss Sleep Quality